Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Benign prostatic hyperplasia
Dutasteride
Phosphodiesterase type 5 inhibitor
Tadalafil
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
05 Sep 2022
05 Sep 2022
Historique:
received:
30
05
2022
accepted:
27
08
2022
entrez:
6
9
2022
pubmed:
7
9
2022
medline:
8
9
2022
Statut:
epublish
Résumé
To evaluate the efficacy and safety of add-on therapy with the phosphodiesterase type 5 inhibitor tadalafil in Japanese men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with dutasteride. Twenty-four patients were enrolled. The participants had a median age of 71.0 (64.8-73.0) years and a median prostate volume of 37.3 (29.7-41.8) mL as measured using transabdominal sonography. The efficacy indicators, such as International Prostate Symptom Score (IPSS), quality of life (QOL) score, night-time urinary frequency, and night-time maximum voided volume, improved significantly at 4 weeks, and the effects lasted until 24 weeks (IPSS: 9.5 vs. 17.0, QOL: 2.0 vs. 4.0, nocturia: 2.0 vs. 2.0, night-time maximum voided volume: 290.0 vs. 240.0 mL). Overactive bladder symptom score (OABSS) and sexual health inventory for men (SHIM) significantly improved at 12 weeks, and the effects lasted until 24 weeks (OABSS: 3.0 vs. 5.0, SHIM: 11.0 vs. 7.5). However, maximum urine flow and residual urine volume showed no improvement at any point. Adverse events occurred in two cases. Taken together, add-on therapy with tadalafil was effective for patients with LUTS/BPH resistant to dutasteride monotherapy. In addition, this therapy was not associated with severe adverse events.
Identifiants
pubmed: 36064733
doi: 10.1186/s13104-022-06183-0
pii: 10.1186/s13104-022-06183-0
pmc: PMC9446813
doi:
Substances chimiques
Tadalafil
742SXX0ICT
Dutasteride
O0J6XJN02I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
288Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
J Urol. 2014 Mar;191(3):727-33
pubmed: 24096118
BJU Int. 2018 Apr;121(4):647-658
pubmed: 29044968
Prostate Int. 2020 Jun;8(2):78-84
pubmed: 32647644
Pharmacopsychiatry. 2016 Jan;49(1):3-13
pubmed: 26569417
Aging Male. 2020 Dec;23(5):501-506
pubmed: 30457437
Int J Urol. 2013 Apr;20(4):421-8
pubmed: 22989348
J Urol. 2008 Sep;180(3):1030-2; discussion 1032-3
pubmed: 18639298
Eur Urol. 2003 Dec;44(6):637-49
pubmed: 14644114
Eur Urol. 2012 May;61(5):994-1003
pubmed: 22405510
Aging Male. 2016 Jun;19(2):111-6
pubmed: 26964647
Int J Urol. 2006 Oct;13(10):1311-6
pubmed: 17010010
Int J Urol. 2011 Mar;18(3):225-30
pubmed: 21272091
Arch Intern Med. 2006 Nov 27;166(21):2381-7
pubmed: 17130393
J Urol. 1996 Apr;155(4):1324-7
pubmed: 8632564
Int J Urol. 2014 Aug;21(8):826-30
pubmed: 24661225
Neurourol Urodyn. 2013 Nov;32(8):1123-7
pubmed: 23861329
J Urol. 2017 Oct;198(4):905-912
pubmed: 28499730
Eur Urol. 2012 May;61(5):917-25
pubmed: 22297243
J Urol. 1995 Aug;154(2 Pt 1):391-5
pubmed: 7541852
Eur Urol. 2010 Jan;57(1):123-31
pubmed: 19825505
Int J Urol. 2017 Jun;24(6):476-477
pubmed: 28429834
Int Urol Nephrol. 2022 Jun;54(6):1193-1198
pubmed: 35362820
Int J Urol. 2013 Feb;20(2):193-201
pubmed: 22958078
Curr Urol Rep. 2004 Aug;5(4):251-7
pubmed: 15260924
Neurourol Urodyn. 2013 Mar;32(3):230-7
pubmed: 22847394
Asian J Urol. 2022 Jan;9(1):42-50
pubmed: 35198395
BJU Int. 2011 Aug;108(3):388-94
pubmed: 21631695